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Abstract
Pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED) are skeletal disorders resulting from
mutations in COMP, matrilin-3 or collagen IX and are characterised by short-limbed dwarfism and premature
osteoarthritis. Interestingly, recent reports suggest patients can also manifest with muscle weakness. Here we
present a detailed analysis of two mouse models of the PSACH/MED disease spectrum; ΔD469 T3-COMP (PSACH)
and V194D matrilin-3 (MED). In grip test experiments T3-COMP mice were weaker than wild-type littermates,
whereas V194D mice behaved as controls, confirming that short-limbed dwarfism alone does not contribute to
PSACH/MED-related muscle weakness. Muscles from T3-COMP mice showed an increase in centronuclear fibers at
the myotendinous junction. T3-COMP tendons became more lax in cyclic testing and showed thicker collagen fibers
when compared with wild-type tissue; matrilin-3 mutant tissues were indistinguishable from controls. This
comprehensive study of the myopathy associated with PSACH/MED mutations enables a better understanding of the
disease progression, confirms that it is genotype specific and that the limb weakness originates from muscle and
tendon pathology rather than short-limbed dwarfism itself. Since some patients are primarily diagnosed with
neuromuscular symptoms, this study will facilitate better awareness of the differential diagnoses that might be
associated with the PSACH/MED spectrum and subsequent care of PSACH/MED patients.
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Introduction
Pseudoachondroplasia (PSACH) and multiple epiphyseal
dysplasia (MED) are skeletal dysplasias associated with short
limbed (upper and lower limbs) dwarfism, lower limb
deformities and early onset osteoarthritis [1,2]. They form a
distinct spectrum of disease severity and the autosomal
dominant forms result from mutations in the genes encoding
three extracellular matrix (ECM) molecules, cartilage oligomeric
matrix protein (COMP; PSACH and severe MED) [1,3],
matrilin-3 (MED) [4] and type IX collagen (MED) [5,6]. PSACH
and MED are defined as skeletal dysplasias, or
chondrodysplasias, indicating the underlying cartilage
pathology. However, patients with these diseases
(predominantly those with COMP and type IX collagen gene
mutations) are occasionally referred to neuromuscular clinics
with symptoms of a ‘non-defined’ mild myopathy before being
correctly diagnosed with chondrodysplasia [7-9]. Despite the
incorrect referrals and misdiagnoses, little is still known about
the effect of these mutant cartilage proteins on the
musculoskeletal system as a whole.
COMP is a large pentameric glycoprotein found in cartilage,
ligament, muscle and bone [10,11] and as an extracellular
matrix (ECM) bridging molecule it is able to interact with
fibronectin [12], aggrecan [13], matrilins [14], collagens [15,16]
and integrins [17,18]. PSACH and MED mutations in COMP
cluster in two distinct regions of the molecule, namely the
thrombospondin type 3 (T3-COMP) repeats and a globular C-
terminal domain (CTD-COMP) [7,19]. COMP containing type 3
repeat mutations is partially retained within the ER of
chondrocytes from PSACH and MED patients [20] and in
various transgenic mouse models, resulting in increased
apoptosis and decreased proliferation in the cartilage growth
plate [21,22]. However, COMP with the common ΔD469 T3
mutation is secreted in both in the ligaments [15] and
tendon[10]. The ECM of mutant cartilage and ligament is also
abnormal with more pronounced appearing collagen fibrils in
cartilage and a disorganised collagen fibrillar network in the
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ligament, both of which are suggestive of reduced fibril surface-
associated molecules [15,22]. In contrast, COMP containing a
variety of CTD mutations can be efficiently secreted into the
extracellular matrix (ECM) of cartilage although there may still
be mild ER stress in chondrocytes [7,23]. There is also
dysregulated apoptosis and decreased proliferation in the
growth plates of CTD-COMP mutant mice and the cartilage
ECM is abnormal with similarly pronounced collagen fibrils [24].
We have previously shown that COMP is expressed in skeletal
muscle, Achilles and patellar tendon and spinal ligament of
mice at different ages and that mild myopathy associated with
a CTD-COMP mutation is due to an underlying tendinopathy
[25] and hypothesised that this pathological feature was most
likely due to the role that COMP plays as a catalyst in collagen
fibrillogenesis [16,25]. We have previously described clinical
data suggesting that myopathy can also be associated with T3-
COMP mutations in patients with PSACH and MED [9,26].
Several patients with type IX collagen mutations presenting
with MED and mild myopathy have recently been described
[8,9]. Moreover, muscle biopsy from a type IX collagen MED
patient showed variability in muscle fiber diameters but normal
collagen fibers in the perimysial tissue (cross ectional area,
fiber distribution and fiber spacing) [27], indicating that type IX
collagen mutations may have a direct effect on muscle
morphology.
Matrilin-3 is a tetrameric molecule found predominantly in
cartilage and can interact with numerous other ECM molecules
including COMP [14,28-30] and type IX collagen [31]. MED
mutations cluster predominantly in the β-sheets of the single A-
domain of matrilin-3 and result in a canonical ER stress
response with dysregulated chondrocyte apoptosis and
decreased proliferation in the cartilage growth plate. Denser
collagen fibrils in the ECM are also observed when examined
by electron microscopy [4,32-34]. Matrilin-3 is thought to be
expressed solely in cartilage [29], however, we have previously
reported a single MED patient (p.D171..177Edel_insE in
matrilin-3) presenting with fatigue during walking which was
diagnosed as a neuromuscular condition [26]. This phenotypic
presentation suggested a potential influence of mutant
matrilin-3 on lower limb weakness, either via underlying
muscle/tendon pathology or the indirect result of short-limbed
dwarfism on the lower limb strength.
In this paper we present the analysis of three knock-in
mouse models of the PSACH/MED disease spectrum, ΔD469
COMP (T3-COMP; PSACH model), T585M COMP (CTD-
COMP; mild PSACH model) and V194D matrilin-3 (moderate
MED model) [22,34]. We conclude that the PSACH/MED
related mild myopathy correlates predominantly with COMP
mutations but not a matrilin-3 mutation. This genotype-specific
delineation and the detailed analysis of the myopathy and
tendinopathy in PSACH and MED mice models will ultimately
help in the diagnosis and clinical management of PSACH/MED
patients.
Materials and Methods
Transgenic mouse models of PSACH and MED
The experimental animal models used in this paper (T585M
COMP, ΔD469 COMP and V194D MATN3 mice) were
generated as described previously [22,24,34]. As described in
these papers the targeting strategy used to generate the
knock-in mice was different for the matrilin-3 and the COMP
mice. Therefore, appropriate wild type controls of the correct
genetic background were generated during standard breeding
procedures. Mice homozygous for the relevant mutations were
chosen for this study in order to accentuate the muscle and
tendon pathology. All experiments were approved by the
University Animal Ethical Review Group and performed in
compliance with the Scientific Procedures Act of 1986 and the
relevant Home Office (under PPL 40/2884) and Institutional
regulations governing animal breeding and handling.
Bone length and grip strength measurement
Wild type and mutant male mice were X-rayed at 3 and 9
weeks of age and Growbase (Certus Technologies) software
was used to measure the humeri and the ulnae lengths. Grip
strength measurements were performed using a hand-held
Chatillon digital force gauge (ChatillonDFE Series Digital Force
Gauge, Ametek Inc.) as described previously [25]. Briefly, the
mice were preconditioned 20 times on the cage lid then held by
the tail and gently lowered towards the apparatus. They were
allowed to grip the grid with their forelimbs only and were
gently pulled backwards in a horizontal plane. The highest
force applied to the grid by the animal (maximum strength) and
the force at the moment the grasp was released was recorded.
The test was repeated two times per mouse and 10 male mice
per genotype were tested at 3 and 9 weeks of age. One-way
ANOVA was used for statistical analysis of the data.
Tissue histology
Full mouse limbs were skinned and fixed in ice-cold 10 %
neutral buffered formalin solution (Sigma-Aldrich Ltd; for
histology) or in ice-cold 95 % ethanol/5 % acetic acid solution
(for immunohistochemistry), decalcified in 20 % (w/v) EDTA pH
7.4 for two weeks, paraffin-embedded and sectioned (6 µm
sections). Gomori's trichrome staining (Polysciences Inc.) was
performed according to the manufacturer's protocol on
transverse limb sections and mounted using a xylene-based
mounting solution (Pertex, Surgipath). 3 male mice per
genotype were analysed at 3 weeks of age. Muscle fibres with
central nuclei were counted and their number was expressed
as a percentage of all the muscle fibres seen. One-way
ANOVA was used for statistical analysis.
For immunohistochemical analysis, slides with saggital limb
sections were dewaxed and rehydrated, endogenous
peroxidase activity was quenched in H2O2/MetOH, followed by
antigen unmasking in 0.2 % bovine testes hyaluronidase
(Sigma-Aldrich Ltd) in PBS. Samples were blocked in goat
serum and 1 % BSA in PBS for 1 h and immediately incubated
with primary antibody [COMP (Genetex Inc.), matrilin-3 (R&D),
collagen IX (made in-house)] in PBS/BSA for 1 h. Slides were
washed in PBS/BSA and incubated with a biotinylated goat
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anti-rabbit IgG (Dako Cytomation Ltd) in PBS with goat serum,
followed by incubation with ABC/HRP reagent (Dako
Cytomation Ltd) and developed using DAB chromogen (Dako
Cytomation Ltd), with methyl green as counter stain (Vector
Labs Ltd). Vectamount™ (Vector Labs Ltd) xylene-free
mounting medium was used for mounting the slides.
Tendon ultrastructure
Wild-type and mutant Achilles tendons were dissected from
mice at 3 weeks of age and immediately fixed in 2.5 %
glutaraldehyde in 0.1 M sodium cacodylate buffer for 2 h at 4
°C. The tissues were washed three times in 0.1 M sodium
cacodylate buffer and fixed in 2 % OsO4 in 0.1 M cacodylate
buffer for 2 h. They were washed in distilled water and
incubated for 2 h in 2 % aqueous uranyl acetate at 4 °C. The
tendons were then washed in distilled water, dehydrated in
increasing concentrations of acetone (50, 70, 90 and 100 % for
30 min), incubated in propylene oxide to improve resin
penetration and 1:1 solution of resin:propylene oxide and
embedded in TAAB medium slow resin (TAAB Laboratories
Equipment Ltd). Thin 70–80 nm sections were cut with a
diamond knife on a Leica ultramicrotome and placed on
electron microscope grids. Sections on the grids were stained
with silver citrate solution and viewed in a FEI Tecnai 12 Twin
transmission electron microscope operated at an accelerating
voltage of 80 kV. The fiber diameters were measured, the
distribution was analysed for statistical significance using
Mann–Whitney U test and the differences in the individual fiber
frequencies between the animals were assessed using one-
way ANOVA.
Cyclic testing
Cyclic strain test was performed on an Instron 5943 tensile
tester (Instron Ltd.). Achilles tendons were harvested at 3
weeks of age and stored in PBS at −80 °C. They were gently
thawed and the cross-sectional area was assessed by
measuring the thickness in three points along the tendon's
length using a microscope graticule (Fisher Scientific). The
average mouse tendon length was ~5 mm. The tendons were
fitted into the tensile tester as shown in [25] using sandpaper
strengthened clamps and were kept moist in PBS throughout
the experiment. In the cyclic strain test, the starting sample
length was 2 mm; the samples were stretched and relaxed with
a constant strain amplitude of 0.5 for n = 10 cycles (previously
established as toe region for the samples [25]) at the strain rate
of 0.04/s, and the force and displacement were recorded. The
force was normalized against the cross-sectional area, and the
decrease in stress at each cycle was compared between the
wild-type and mutant samples. Sample stiffness was calculated
as F/σ where F=force and σ=displacement. Energy dissipation
was calculated as (Welongation-Wrelease)/(Welongation)Independent
samples one-way ANOVA was used for statistical analysis.
Results
Matrilin-3 is not expressed in mouse muscle or tendon
tissues
The localisation of COMP and matrilin-3 in mouse skeletal
tissues was analysed using immunohistochemical (IHC)
staining performed on saggital sections of 3 week old wild-type
hind limbs (Supplemetal Figure 1). COMP protein was detected
in the cartilage growth plate (GP), articular cartilage (AC),
patellar tendon (PT), meniscus (M), skeletal muscle, Achilles
tendon, fibrocartilage of the endo-osseous junction and in the
myotendinous junction (Figure S1 and data not shown) [26].We
observed no retention of mutant COMP in the skeletal muscle
tissue at 3 weeks (not shown). In contrast, matrilin-3
expression appeared be restricted to cartilage and the protein
was not detected at appreciative levels in other
musculoskeletal tissues (Figure S1).
COMP and matrilin-3 mutant mice have shorter
forelimbs
Bone length measurements were performed at 3 and 9
weeks of age using full skeleton radiographs in order to assess
the length of forearms in wild type and mutant mice (Figure 1).
Appropriate wild type controls of the correct genetic
background were used in all the experiments. The humeri of
both COMP mutant mouse lines were shorter than wild-type
littermates by 9 weeks of age (Figure 1A; CTD-COMP by 7.4%
p<0.05 and T3-COMP by 12.8% p<0.01). There was also a
slight trend towards a decrease in the length of the ulnas at 9
weeks of age (p<0.1 and p<0.09 respectively). V194D
matrilin-3 mutant mice also had shorter humeri at 9 weeks of
age that was in a range similar to the T3-COMP mice (Figure
1B; 14.2% p<0.001). Furthermore, the ulnas were also shorter
at 3 weeks of age (by 4% p<0.01) and showed a similar, albeit
not statistically significant, trend at 9 weeks of age (p<0.5).
COMP mutant mice are weaker than their wild type
littermates
Grip strength measurements were performed as previously
described [25] in order to assess wild type and mutant animal
muscle strength and stamina at 3 and 9 weeks of age (Figure
2). Mutant mice with the T3-COMP mutation (ΔD469) tired
more easily than their wild-type littermates (force on release
was 18.3% lower than the wild types, p<0.01) and were
generally weaker at 9 weeks of age (maximum force was
24.4% lower than wild type controls; p<0.001, n>10). At 3
weeks there was also a trend similar to that previously
described for CTD-COMP (T585M) mice (Figure 2A and [25]).
In contrast, despite short-limbed dwarfism, matrilin-3 mutant
(V194D) mice did not manifest any muscle weakness with age
and all parameters were comparable to wild type littermates at
both time points (Figure 2B, n>10).
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Figure 1.  Bone measurements based on X-rays of 3, 6 and 9 week old mice.  Humeri in COMP mutant mice (A) and in matrilin
3 mutant mice (B) were shorter than in the wild type controls. Error bars; SEM (standard error of the mean; n≥10). Key: * P<0.05, **
P<0.01, *** P<0.001.
doi: 10.1371/journal.pone.0082412.g001
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Figure 2.  Grip strength measurement at 3 and 9 weeks of age.  COMP mutant mice (A) become weaker with age compared to
their littermates whereas the grip strength of matrilin 3 mutant mice (B) remains similar to the wild type littermates at all ages. Error
bars; SEM (standard error of the mean; n≥10). Key: * P<0.05, ** P<0.01, *** P<0.001.
doi: 10.1371/journal.pone.0082412.g002
Myopathy Associated with Genetic Skeletal Diseases
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Gomori trichrome staining of gastrocnemius/soleus
muscle reveals remodelling events in the muscles of
COMP mutant mice
We used modified Gomori trichrome staining to analyse the
morphology of the skeletal muscle (gastrocnemius/soleus) in
transverse sections of hind limbs from the different mouse
models of PSACH and MED. Using this procedure muscle
tissue was stained red, cartilage and collagenous tissue (such
as tendon and ligament) were stained blue and nuclei were
stained black, allowing easy identification of the various tissue
components (Figure 3A; inset). This staining protocol was used
to analyse the general morphology of the skeletal muscle in the
different mouse models and to localise and quantify the muscle
fibers with central nuclei, which are indicative of muscle stress
and remodelling [35,36]. Since defects to any of the
components of the musculoskeletal system may also result in
abnormalities to the other tissues [37,38], muscle and tendon
from mutant matrilin-3 mice were analysed in detail in order to
gain insight into the potential effect of a cartilage and bone
growth defect on the morphology and biomechanical properties
of the adjoining soft tissues.
We have found no histological indication of large scale
muscle atrophy or deterioration in mutant skeletal muscles.
However, T3-COMP mutant muscles contained significantly
more fibers with central nuclei at the myotendinous and
perimysial junctions (Figure 3A, 32.0% p<0.05), which was
similar to the pathology previously reported for CTD-COMP
mice (40.2% p<0.01 in [25]). However, there was also a
significant increase in the total number of muscle fibers with
central nuclei in the rest of the tissue (Figure 3A, 34.2%
p<0.01), which was not the case for CTD-COMP [25]. Since
COMP is expressed in skeletal muscle as well as in tendon and
ligament and the T3-COMP mutations generally have a more
severe phenotypic outcome than the CTD-COMP mutations,
the T3-COMP mutation may have a more pronounced and
measurable effect on the entire skeletal muscle tissue. Mutant
matrilin-3 and wild type muscle showed similar numbers and
distribution of fibers with central nuclei in all areas analysed
(Figure 3B), which further supports our hypothesis that there is
no specific muscle pathology in MATN3-related MED.
Ultrastructure analysis of the collagen fibers in Achilles
tendons reveals genotype specific changes in tendon
morphology
Achilles tendons from 3 week old wild-type and mutant mice
were analysed by transmission electron microscopy (TEM) in
order to determine if the different mutations affected the
morphology and/or ultrastructure of this tissue.
As described previously, CTD-COMP mutant mice had
thinner tendons as 3 weeks of age (Figure 4A and [25]),
however, the cross sectional area of the T3-COMP mutant
tendons was comparable to that of wild type samples (Figure
4A). The distribution of fiber diameters in T3-COMP mutant
Achilles tendons at 3 weeks of age followed a normal bell curve
distribution but broader than the one in wild type mice, with
significantly more thicker fibers present in the mutant tendon
(Figure 4B). A trend towards a bimodal distribution with a
second peak at 160 nm could be seen in the histograms of T3-
COMP tendons. A similar distribution was previously found in
the CTD-COMP tendons at 9 weeks of age and also in ageing
mouse tendons [25,39]. Moreover, the number of fibers per
area were comparable between T3-COMP and wild type mice
(data not shown) indicating potentially less interterritorial matrix
present in the mutant COMP tendons.
Finally, there were more fused/branching collagen fibers
(Figure 4C inset) present in T3-COMP mutant Achilles tendons
at 3 weeks of age (Figure 4C; ~2-fold p<0.05) and we have
previously shown a similar difference for the CTD-COMP
mutation (Figure 4C; ~4-fold p<0.05[25]). The trend towards
the greater number of bifurcating fibers in the CTD-COMP
mutant may be a means for compensating for thinner and
therefore more lax tendons. In contrast, mutant matrilin-3 and
wild type tendons were the same thickness at 3 weeks of age
(Figure 5A) and showed a normal bell curve distribution of
collagen fiber diameters (Figure 5B, no statistically significant
differences). Furthermore, there was no increase in the number
of branching/fused collagen fibers between the wild type and
mutant matrilin-3 tendons (Figure 5C).
Achilles tendons in COMP mutant mice become more
lax in biomechanical cyclic testing
To assess tendon biomechanical properties, wild type and
mutant Achilles tendons from 3 week old mice were used in a
cyclic strain experiment as described previously [25]. Tendons
were stretched through 10 cycles of a constant strain and the
stress at each cycle (measured as force divided by the cross
sectional area) was recorded. The tendons from both mutant
COMP mice became more lax in cyclic testing, which was
indicated by a decrease in both the recorded stress by cycle 10
(Figure 6A) and stiffness (Figure 6B; CTD-COMP 28.2 %
p<0.01 and T3-COMP 32 % p<0.05; n≥3). Furthermore, the
tendons from CTD-COMP mutant mice were significantly more
lax than tendons from T3-COMP mutant mice by cycle 10
(Figure 6A; 17.6 %, p>0.05). Normal energy dissipation for an
animal tendon varies between 8-18 % upon release [40,41].
Energy dissipation values calculated for COMP wild type
tendons fall within this range. COMP mutant tendons were
dissipating more energy than the wild type tissue as the cycling
progressed indicating they were failing in their energy storage
and muscle buffer roles (Figure 6C; CTD-COMP 3-fold p<0.05,
T3-COMP 4-fold p<0.01; n≥3).
Achilles tendons from mutant matrilin-3 mice behaved in a
similar way to wild type tendons in cyclic testing and the
maximum stress, energy loss and stiffness recorded at cycle
10 was comparable to wild type controls (Figure 7A-C),
suggesting that the matrilin-3 mutation has no direct effect on
the biomechanical properties of Achilles tendon in mice.
Discussion
Pseudoachondroplasia (PSACH) and multiple epiphyseal
dysplasia (MED) are skeletal dysplasias associated with short-
limbed dwarfism and early onset osteoarthritis (OA). However,
recent clinical findings suggest that there is also a
neuromuscular component associated with these diseases that
may actually manifest prior to the skeletal phenotype.
Myopathy Associated with Genetic Skeletal Diseases
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Figure 3.  Quantification of the muscle fibers with central nuclei at 3 weeks of age.  Quantification based on images obtained
using the modified Gomori trichrome stain on transverse sections of mouse legs at 3 weeks of age. Inset shows an example of
stained tissue skeletal muscle is stained red, collagenous tissue blue, nuclei black - yellow arrow indicates a muscle fibre with
central nucleus. Mutant COMP mice (A) have more muscle fibers with central nuclei around the myotendinous and perimysial
junction than their wild type littermates. Matrilin 3 mutant mice (B) show similar distribution of fibers with central nuclei as their wild
type littermates. Error bars; SEM (standard error of the mean; n≥3). Key: * P<0.05, ** P<0.01, *** P<0.001.
doi: 10.1371/journal.pone.0082412.g003
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Figure 4.  Analysis of ultrastructure of the mutant COMP Achilles tendon at 3 weeks.  A) Measurement of the cross sectional
area of wild type and mutant tendons. T585M COMP tendons but not ΔD469 COMP mutant tendons were thinner than wild type
controls at 3 weeks, n>10. B) Both COMP mutant tendons contained more of the thicker collagen fibers than the wild type controls,
n=3. C) Both COMP mutant tendons contained more fused/branching collagen fibers when compared to the wild type tissues at 3
weeks of age, n=3. Error bars; SEM (standard error of the mean). Key: * P<0.05, ** P<0.01, *** P<0.001 (t-test).
doi: 10.1371/journal.pone.0082412.g004
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Figure 5.  Analysis of the ultrastructure of the mutant MATN3 Achilles tendon at 3 weeks.  A) Measurement of the cross
sectional area of wild type and mutant tendons. V194D MATN3 tendons were not thinner than wild type controls at 3 weeks, n>10.
B) MATN3 mutant tendons contained similar amounts of both thinner and thicker collagen fibers than the wild type controls, n=3. C)
MATN3 mutant tendons contained similar amounts of fused/branching collagen fibers when compared to the wild type tissues at 3
weeks of age, n=3. Error bars; SEM (standard error of the mean). Key: * P<0.05, ** P<0.01, *** P<0.001.
doi: 10.1371/journal.pone.0082412.g005
Myopathy Associated with Genetic Skeletal Diseases
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Figure 6.  Results of the cyclic test experiment on COMP mutant tendons.  A) Stress per cycle plot showing a decrease in
force needed to extend mutant tendons to the same strain as the wild type controls. Note that although both COMP mutant tendons
became more lax in cyclic testing, the ΔD469 COMP tendons become slightly less lax than the T585M COMP tissue by 10th cycle.
B) Calculation of the proportion of energy dissipated by the Achilles tendons in 10th cycle, showing the mutant COMP tendons may
potentially fail as energy storage and buffering elements in mutant hind limbs. C) Tendon stiffness at 10th cycle calculated in relation
to stiffness at cycle 1 (100%) showing mutant COMP tendons becoming more lax than the wild type controls. Error bars; SEM
(standard error of the mean; n≥3). Key: * P<0.05, ** P<0.01, *** P<0.001.
doi: 10.1371/journal.pone.0082412.g006
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Figure 7.  Results of the cyclic test experiment on matrilin 3 mutant tendons.  A) Stress per cycle plot showing a decrease in
force needed to extend mutant tendons to the same strain as the wild type controls. We found no difference between the wild type
and mutant tendons at 3 weeks. B) Calculation of the proportion of energy dissipated by the Achilles tendons in 10th cycle, showing
no difference between the wild type and mutant matrilin 3 tissue at 3 weeks. C) Tendon stiffness at 10th cycle calculated in relation
to stiffness at cycle 1 (100%) showing mutant matrilin 3 tendons did not become more lax than the wild type controls in the cyclic
testing experiment (n≥3).
doi: 10.1371/journal.pone.0082412.g007
Myopathy Associated with Genetic Skeletal Diseases
PLOS ONE | www.plosone.org 11 November 2013 | Volume 8 | Issue 11 | e82412
Furthermore, soft tissue abnormalities such as ligamentous
laxity, myopathy and joint instability may cause, or exacerbate,
the lower limb deformities (such as genu varum and genu
valgum) and may further aggravate the early onset
osteoarthritis seen in PSACH and MED patients [42,43].
Therefore, a thorough characterisation of the tendomuscular
pathology associated with PSACH and MED would enable
better differential diagnosis and clinical management of
affected individuals.
Patients with PSACH/MED and CTD-COMP or type IX
collagen mutations presenting with ‘neuromuscular-like’
symptoms prior to a correct diagnosis of skeletal dysplasia
have been described on several occasions [7-9,26,27,44].
Based on these reports we have previously analysed a CTD-
COMP (T585M) model of mild PSACH and demonstrated that
muscle weakness in this mouse was due to an underlying
tendinopathy [25]. As a result of recent findings describing
neuromuscular-like symptoms in T3-COMP and possibly
MATN3 patients [9,26], we wished to characterise the muscle
and tendon phenotype in two further mouse models of the
PSACH/MED spectrum; the Comp ΔD469 [22] and Matn3
V194D [34] models of severe PSACH and moderate MED
respectively.
Cartilage oligomeric matrix protein (COMP) is a large
pentameric glycoprotein expressed in skeletal muscle and
tendon/ligament as well as in cartilage [10,11,25]. Type IX
collagen is found in cartilage [45,46], fibrocartilage [47] and
vitreous of the eye [45], whilst some reports also describe the
mRNA of at least one of the type IX collagen chains in skeletal
muscle [27,48]. The expression of matrilin-3 has only been
reported in cartilage to date [29,49,50]. We therefore decided
to confirm the expression of these molecules in mouse tissues
before proceeding with further biological experiments. Using
immunohistochemistry and real time PCR [25] we have
confirmed that COMP is expressed in skeletal muscle,
myotendinous junction, fibrocartilage, Achilles and patellar
tendon in the hind limb and spinal ligament at 3 weeks of age,
as well the cartilaginous growth plate. We were also able to
show that type IX collagen is present in cartilage, fibrocartilage
at the tendo-osseous junction and to a much lesser extent in
the skeletal muscle (not shown). In contrast, matrilin-3 was only
detectable in cartilage thus confirming its restricted distribution.
We measured the bone lengths of forelimbs in our
experimental models prior to mechanical testing and
determined that short-limbed dwarfism was within a similar
range for all the models tested. We then performed grip test
measurements and found that T3-COMP mutant mice were
weaker at 9 weeks of age and tired more easily than their wild
type littermates, thus confirming a similar trend in progressive
muscle weakness as previously published for CTD-COMP mice
[25]. However, in contrast, V194D matrilin-3 mice did not show
any signs of muscle weakness or fatigue at 3 or 9 weeks of
age, thus proving that the muscle weakness observed in
patients of the PSACH/MED disease spectrum is not the result
of short limbed dwarfism alone.
We next performed a histological examination of the skeletal
muscle morphology in our mouse models and counted the
incidence of muscle fibers with central nuclei. Such fibers are
common in foetal muscles [51] and in adult muscle are an
indicator of myofiber stress and remodelling [35,36]. We found
an increase in the amount of fibers with central nuclei at the
myotendinous and perimysial junctions in both COMP mutant
models at 3 weeks of age, indicating that the COMP-related
myopathy is potentially due to an abnormality in the
collagenous connective tissues surrounding the muscle itself.
The morphology of skeletal muscle in the matrilin-3 mutant
mice was normal, thus confirming that the shorter bones in the
matrilin-3 mutant mice do not affect muscle regeneration and
remodelling.
Ultrastructural studies of the Achilles tendons at 3 weeks of
age were performed to assess the effect of mutant proteins on
tendon morphology. We found that although the collagen fiber
diameters in both COMP mutant tendons did follow the normal
distribution, CTD-COMP and T3-COMP mutant tendons both
contained thicker collagen fibers when compared to the wild
type controls, further confirming our previously reported
observations for the CTD-COMP mutant mice [25]. The total
cross sectional area of T3-COMP mutant tendons was similar
to the wild type tissues, unlike the thinner tendons in the CTD-
COMP mutant mice [25]. The fibers per area count was
comparable for T3-COMP and wild type mice which in
conjunction with the finding of thicker collagen fibers in the
mutant tendon indicates potentially less interterritorial matrix
present in the ΔD469 mutant COMP tendons. Proteoglycans in
the tendon ECM are important for water retention and
lubrication of the tissue and may therefore influence its
biomechanical properties [52]. Previous studies of a transgenic
ΔD469 COMP mouse model showed a partial loss of
proteoglycans and aggrecan in the interterritorial matrix of
growth plate cartilage [53]. It is therefore tempting to speculate
that the T3-COMP mutation would have a similar effect on the
interterritorial matrix in the Achilles tendon.
By contrast, the fibers per area count was lower for CTD-
COMP mice than for the wild type controls and the amount of
extracellular matrix proteoglycans appeared comparable to the
wild type controls (by DMMB staining when normalised to DNA
content [25]). CTD-COMP tendons were also significantly
thinner than the wild type tissues, indicating that a CTD-COMP
mutation may have a more profound effect on ECM
composition and its ability to swell and retain water during the
measurement of tendon diameters in PBS. Furthermore, it is
known that intermittent high loads (such as running) may result
in a larger tendon cross-sectional area. Since CTD-COMP
mice were the only mouse model where early onset OA was
documented [24], they may have also been less active; this
may in turn have resulted in thinner Achilles tendons. However,
this aspect of PSACH/MED tendon biology remains to be
clarified.
T3-COMP mutant tendons contained more fused/bifurcating
collagen fibers than the wild type tissues, again recapitulating
the phenotype seen in CTD-COMP mice and possibly
indicative of microdamage/remodelling in the tendon. Such a
feature is normally observed in foetal tendon and in adult
tendon scar tissue [54,55]. It is thought that bridges between
the collagen fibers may be an attempt to strengthen the
biomechanical properties of the tissue, and in the case of
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COMP-related tendinopathies it may be a way to compensate
for the increased tissue laxity. Similar bifurcating collagen
fibers have also been reported in PSACH patients [15,25]. In
contrast, no structural abnormalities were found in the
matrilin-3 mutant tendons thus confirming again that short
limbed dwarfism per se does not have an effect on the
musculoskeletal system.
We tested the biomechanical properties of wild type and
mutant tissues using the cyclic strain test at 3 weeks of age
[25]. We found that the T3-COMP mutant Achilles tendons
became more lax with cyclic testing, similar to what we have
previously shown for CTD-COMP mutants [25] and again
repeated in this study. Moreover, changes in tissue stiffness
calculated for the first and last cycle pointed to increased
tendon laxity in COMP mutant tendons. However, it seemed
that the ΔD469 COMP tendons were slightly more resilient to
stretching than the T585M COMP tissue, especially by the last
cycle, which could be due to the larger cross sectional area
and the fiber per area count of the T3-COMP mutant tendon
compared to the CTD-COMP tissue. The observed laxity of the
mutant tendon under stretch conditions possibly recapitulates
the joint laxity seen in COMP-associated PSACH/MED patients
which in turn may potentially exacerbate disease complications
such as early onset OA [56]. In addition, COMP mutant
tendons dissipated more energy during cyclic strain testing
than the wild type controls, indicating that their energy storage
potential and the role of buffer for the skeletal muscle were
somewhat impaired during the test. This may in turn explain
why the pathology in the skeletal muscle is seen predominantly
at the myotendinous junction and perimysial junctions, which
are the collagenous fibrous tissues important for conveying
forces between tendon and the muscle [52,57,58]. In contrast,
matrilin-3 mutant Achilles tendons behaved similar to wild type
tissues in the cyclic test and did not become more lax than the
controls. This is in correlation with the disease profile of the
majority of matrilin-3 MED patients, whereby only skeletal
development is affected and there are no soft tissue
complications [56]. We can only surmise that the matrilin-3
patient previously reported in our cohort (D171..177Edel_insE)
carries an unrelated mutation leading to the muscle weakness
phenotype, or alternatively, since matrilin-3 is also expressed in
the calcaneous perhaps such a large deletion may lead to a
gross protein malfunction and further tissue instabilities at this
attachment point.
Overall, our data suggest that PSACH/MED related muscle
weakness correlates with mutations in COMP but not in
matrilin-3. This is in agreement with the spatial distribution of
these two proteins in the mouse hind limb and the role these
proteins play in the musculoskeletal tissues. COMP is a know
catalyst of collagen fibrillogenesis [16] and is present in the
interterritorial matrix in tendon [11]. Studies in horses have
shown it to be an important factor in tendon growth [59].
Furthermore, CTD-COMP mutations have been shown
previously to lead to thicker amorphous collagen fibers in vitro
[60] and both CTD- and T3-COMP mutant mice show
differences in the ultrastructure of extracellular matrix in the
growth plate cartilage [22,24]. It is therefore plausible to
hypothesise that mutations in COMP affect collagen
fibrillogenesis in mutant tendons as well. This may then lead to
changes in the biomechanical properties of the tissue, joint
laxity, insufficient energy storage, force distribution and
buffering during walking and other motor activities leading in
turn to the observed lower limb weakness. Our data presented
in this paper supports this hypothesis. Furthermore, it has been
suggested that ageing may enhance MMP-related
degeneration of the ECM in cyclically strained tendon, which
can be measured by the release of COMP fragments and
subsequent loss of tensile strength [61]. It is therefore
interesting to speculate this process could be further
exacerbated in the case of PSACH/MED structurally abnormal
tendons.
Type IX collagen related MED with a myopathy has been
reported previously [8,27]. A biopsy of skeletal muscle of an
MED patient with COL9A3 mutation showed variability in
muscle fiber diameters with normal perimysial morphology [27]
indicating that mutant type IX collagen may have a direct effect
on the skeletal muscle morphology and function. However, a
mouse model is currently not available for analysis and the
musculoskeletal complications related to type IX collagen
mutations remain to be investigated further.
Conclusions
To conclude, the tendomuscular complications in
PSACH/MED patients are often diagnosed based on changes
in muscle strength,. This detailed analysis of the muscle and
tendon phenotype in PSACH/MED mouse models has revealed
that pathological changes in the skeletal muscle are located in
certain specific areas (in particular the myotendinous and
perimysial junction) and stem from an underlying tendon
defect. The severe end of the PSACH/MED disease spectrum
is caused exclusively by the mutations in COMP, the molecule
with the broadest tissue distribution and direct involvement in
collagen fibrillogenesis. It is therefore interesting to speculate
that if indeed the muscle weakness and tendon/ligament laxity
have an effect on subsequent disease severity and
complications (such as the severity of the observed
osteoarthritis or lower limb deformities), perhaps some of those
features could be alleviated with a tailored physiotherapy
regime and better patient management in the future [62-65].
Supporting Information
Figure S1.  Localisation of COMP and matrilin 3 in
musculoskeletal tissues. A) in knee joint, B) skeletal muscle
(immunohistochemistry, brown staining). Negative control was
generated following the standard staining procedure with no
primary antibody. Scale bar 200μm. Key: GP-growth plate
cartilage, AC-articular cartilage, M-meniscus, PT-patellar
tendon.
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